Biotech Archives - Page 51 of 795

3 minute read

In Vivo Efficacy Of Matinas BioPharma’s Oral MAT2203 In Pulmonary Mucormycosis Published In Journal Of Antimicrobial Agents And Chemotherapy

April 30, 8:16 AM

Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that

MTNB

2 minute read

Soleno Therapeutics Announces Peer-Reviewed Publication Of Data Comparing DCCR Treatment To The Natural History Of Prader-Willi Syndrome

By Benzinga Newsdesk

April 30, 8:15 AM

Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the publication of the comparison of results

SLNO

2 minute read

Ultragenyx Announces Completion Of Enrollment In Phase 3 Orbit And Cosmic Studies Evaluating Setrusumab For The Treatment Of Osteogenesis Imperfecta

By Benzinga Newsdesk

April 30, 8:11 AM

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies evaluating setrusumab (UX143) in pediatric and young adult patients with

RARE

2 minute read

Biora Therapeutics Announces Completion Of Multiple-Ascending Dose Cohorts For Clinical Trial Of BT-600

By Benzinga Newsdesk

April 30, 8:07 AM

Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late Q2 2024SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the

BIOR

1 minute read

Eagle Pharmaceuticals Announces A Trial In Progress Presentation Of Phase 2/3 Study Of Intravenous Amisulpride As Prevention Of Postoperative Nausea And Vomiting In Pediatric Patients At The Upcoming Society For Ambulatory Anesthesia 2024 Annual Meetin…

By Benzinga Newsdesk

April 30, 8:06 AM

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 study of intravenous amisulpride as a

EGRX

3 minute read

Rhythm Pharmaceuticals Announces Publication Of Results From Phase 2 Study Of Setmelanotide For The Treatment Of Hypothalamic Obesity In The Lancet Diabetes & Endocrinology

By Benzinga Newsdesk

April 29, 6:49 PM

- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment - - Topline data from ongoing pivotal Phase 3 clinical

RYTM

4 minute read

Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study Of Allosteric BCR-ABL Inhibitor TERN-701 In Adult Healthy Volunteers And Highlights Potential For Competitive Differentiation

By Benzinga Newsdesk

April 29, 4:31 PM

Ability to dose TERN-701 without regard to food represents a key potential differentiator within the allosteric BCR-ABL inhibitor classPharmacokinetic data show no clinically significant difference in exposure

TERN

1 minute read

Cytokinetics To Host Investor Event And Conference Call To Discuss The Primary Results From SEQUOIA-HCM At The European Society Of Cardiology Heart Failure 2024 Congress

By Benzinga Newsdesk

April 29, 4:03 PM

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced it will host an investor event and conference call on May 13, 2024 at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) to discuss the primary results

CYTK

2 minute read

AstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very Rare Case, But Causal Mechanism Unknown

By Vandana Singh

April 29, 2:38 PM

Discover the latest on AstraZeneca's Covid vaccine lawsuit. Allegations of serious side effects, including fatalities and brain injuries, spark legal battles. Learn about the controversy and potential ramifications.

AZN

2 minute read

Why Is Alzheimer’s-Focused Annovis Bio Stock Nosediving On Monday?

By Vandana Singh

April 29, 1:53 PM

Annovis Bio faces setbacks in Phase 2/3 Alzheimer's study, revealing minimal change in patients' conditions. Despite slight improvements in mild cases, results show no significant difference in treatment groups.

ANVS